Summit on Cell Therapy for Cancer

November 1-2, 2011
Masur Auditorium on the NIH Campus
Building 10, Clinical Center
Bethesda, MD

The 1½ day Summit on Cell Therapy for Cancer included dynamic discussions and lectures by leaders in the field to provide an in-depth review of the state-of the art of cell therapy as a cancer immunotherapy. The program included presentations on the latest research on the following topics.

Topics Addressed

• Induced Pluripotent Stem Cells
• Reprogramming Immune Cells and Translational Considerations
• Various Cell Therapy Modalities
• Regulatory Considerations for Cell Therapies
• Methods for T Cell Expansion
• Evaluation of Biomarkers for T Cell Therapies
• Adoptive Immune Therapies for Melanoma
• Persistence of Transferred Cells
• Differentiation of Human and Mouse Immune Stem Cells
• Clinical Trials That Will Impact Cell Therapies: The CITN Perspective
   

Organizers

David F. Stroncek, MD – National Institutes of Health (NIH)
John O’Shea, MD – National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
Cornelis J.M. Melief, MD, PhD – Leiden University Medical Center

 Participating Organizations

AABB (formerly the American Association of Blood Banks)
American Society for Blood and Marrow Transplantation (ASBMT)
American Society of Gene & Cell Therapy (ASGCT)
Cancer Immunotherapy Trials Network (CITN)
National Institutes of Health, Clinical Center, Department of Transfusion Medicine